Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1960 : HuCCT1  update : 2021/05/20
CommentHuman bile duct carcinoma. This cell line produces carbohydrate antigen 19/9 in serum-free medium. TKG0389 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Obinata, Masuo
Originator Miyagiwa, M. (Okayama Univ.)
Year of deposit 2004
Original cell TKG0389
Animal _human < Mammals
Genus Homo
Species sapiens
Age at sampling 56 years
Tissue bile duct, ascites meta
Disease name bile duct carcinoma.
Metastastatic ability Yes
Metastatsd tissue asites
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0389)
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_0324
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 2
User's Publication 77


To topTop
Reference
5058  Matsuzaki K, Yoshitake Y, Miyagiwa M, Minemura M, Tanaka M, Sasaki H, Nishikawa K.  Production of basic fibroblast growth factor-like factor by cultured human cholangiocellular carcinoma cells.  Jpn J Cancer Res  1990  81(4):345-54  PubMed ID: 2163997
3279  Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H  A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium  In Vitro Cell Dev Biol Anim  1989  25:503-510  PubMed ID: 2544546

To topTop
User's Publication
13410  Saijoh S, Nakamura-Shima M, Shibuya-Takahashi R, Ito R, Sugawara A, Yamazaki T, Imai T, Asada Y, Matsuura K, Iwai W, Wakui Y, Abue M, Kawamura S, Katayose Y, Fujimori H, Mochizuki M, Yasuda J, Yamaguchi K, Sugamura K, Satoh K, Katori Y, Tamai K.  Discovery of a chemical compound that suppresses expression of BEX2, a dormant cancer stem cell-related protein.  Biochem Biophys Res Commun  2021    PubMed ID: 33412384
13485  Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M, Sakamoto N.  Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes  Cancer Sci  2021  112(2):828-838  PubMed ID: 33345417
20017  Rose S, Ezan F, Cuvellier M, Bruyère A, Legagneux V, Langouët S, Baffet G.  Generation of proliferating human adult hepatocytes using optimized 3D culture conditions.  Sci Rep  2021  11(1):515  PubMed ID: 33436872
13539  Nagaoka K, Ogawa K, Ji C, Cao KY, Bai X, Mulla J, Cheng Z, Wands JR, Huang CK.  Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis  Dig Dis Sci  2021  66(4):1080-1089  PubMed ID: 32445050
20163  Nam AR, Yoon J, Jin MH, Bang JH, Oh KS, Seo HR, Kim JM, Kim TY, Oh DY.  ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.  Cancer Lett  2021  516:38-47  PubMed ID: 34082024
20178  Cen W, Li J, Tong C, Zhang W, Zhao Y, Lu B, Yu J.  Intrahepatic Cholangiocarcinoma Cells Promote Epithelial-mesenchymal Transition of Hepatocellular Carcinoma Cells by Secreting LAMC2.  J Cancer  2021  12(12):3448-3457  PubMed ID: 33995623
20228  Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma.  Takemura Y, Ojima H, Oshima G, Shinoda M, Hasegawa Y, Kitago M, Yagi H, Abe Y, Hori S, Fujii-Nishimura Y, Kubota N, Masuda Y, Hibi T, Sakamoto M, Kitagawa Y.  Cancer Med  2021    PubMed ID: 34245137
15516  Hozaka Y, Seki N, Tanaka T, Asai S, Moriya S, Idichi T, Wada M, Tanoue K, Kawasaki Y, Mataki Y, Kurahara H, Ohtsuka T.  Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma  ancers (Basel)   2021  13(11):2804  PubMed ID: 34199886
12007  Win Maung HM, Chan-On W, Kunkeaw N, Khaenam P.  Common transcriptional programs and the role of chemokine (C-C motif) ligand 20 (CCL20) in cell migration of cholangiocarcinoma.  EXCLI J  2020    PubMed ID: 32194362
12036  San TT, Khaenam P, Prachayasittikul V, Sripa B, Kunkeaw N, Chan-On W.  Curcumin enhances chemotherapeutic effects and suppresses ANGPTL4 in anoikis-resistant cholangiocarcinoma cells.  Heliyon  2020    PubMed ID: 32051864
12044  Fukuda Y, Asaoka T, Eguchi H, Yokota Y, Kubo M, Kinoshita M, Urakawa S, Iwagami Y, Tomimaru Y, Akita H, Noda T, Gotoh K, Kobayashi S, Hirata M, Wada H, Mori M, Doki Y.  Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma.  Cancer Sci.  2020    PubMed ID: 31799781
12462  Yoshino J, Akiyama Y, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S.  Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma  Carcinogenesis  2020  41(6):734-742  PubMed ID: 31665232
12987  Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, Ma X, Gong Y, Holland EC, Huse JT, Chan TA.  Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.  Sci Adv  2020    PubMed ID: 32494639
13005  Hsieh CH, Chu CY, Lin SE, Yang YSH, Chang HS, Yen Y.  TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma.  Cancers (Basel)  2020    PubMed ID: 32365487
13336  Pan YR, Wu CE, Yeh CN.  ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.  Biomolecules  2020    PubMed ID: 33182492
13552  Nam AR, Jin MH, Bang JH, Oh KS, Seo HR, Oh DY, Bang YJ.  Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer  Cancer Res Treat  2020  52(3):945-956  PubMed ID: 32311864
13897  Liu F, Zhu C, Gao P, Zheng S, Li C.  Ubiquitin-conjugating enzyme E2T regulates cell proliferation and migration in cholangiocarcinoma  Anticancer Drugs  2020  31(8):836-846  PubMed ID: 32796405
13917  Tamai K, Nakamura-Shima M, Shibuya-Takahashi R, Kanno SI, Yasui A, Mochizuki M, Iwai W, Wakui Y, Abue M, Yamamoto K, Miura K, Mizuma M, Unno M, Kawamura S, Sato I, Yasuda J, Yamaguchi K,   BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma  Sci Rep  2020  10(1):21592  PubMed ID: 33299012
11443  Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P.  GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.  Invest New Drugs  2019    PubMed ID: 30778887
11459  Farley AM, Braxton DR, Li J, Trounson K, Sakar-Dey S, Nayer B, Ikeda T, Lau KX, Hardikar W, Hasegawa K, Pera MF.  Antibodies to a CA 19-9 Related Antigen Complex Identify SOX9 Expressing Progenitor Cells In Human Foetal Pancreas and Pancreatic Adenocarcinoma.  Sci Rep  2019    PubMed ID: 30814526
11476  Wei K, Li M, Zöller M, Wang M, Mehrabi A, Hoffmann K.  Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.  Cell Death Dis  2019    PubMed ID: 30850583
4244  Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ.  Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.  Cancer Res Treat  2019  51(3):1167-1179  PubMed ID: 30514066
4245  Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ.  Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.  Cancer Res Treat  2019  51(3):886-900  PubMed ID: 30282449
3737  Sakamoto Y, Yamagishi S, Okusaka T, Ojima H.  Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.  Cells  2019  8(9):1026  PubMed ID: 31484399
14816  Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.  TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma  Cancer Discov  2019  9(8):1064-1079  PubMed ID: 31109923
10684  Kawashita Y, Morine Y, Saito Y, Takasu C, Ikemoto T, Iwahashi S, Teraoku H, Yoshikawa M, Imura S, Yagi T, Shimada M.  Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas.  J. Gastroenterol. Hepatol.  2018  33(7):1407-1412  PubMed ID: 29278438
10740  Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P, Fautrel A, Turlin B, Clément B, Dooley S, Sulpice L, Boudjema K, Coulouarn C.  A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma.  Hepatol Commun  2018  2:254-269  PubMed ID: 29507901
10759  Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.  PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.  Jpn. J. Clin. Oncol.  2018  48:396-399  PubMed ID: 29474549
11330  Komatsu N, Kajiya M, Motoike S, Takewaki M, Horikoshi S, Iwata T, Ouhara K, Takeda K, Matsuda S, Fujita T, Kurihara H.  Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes.  Stem Cell Res Ther  2018    PubMed ID: 30526677
11345  Kim J, Kim H, Lee JC, Kim JW, Paik WH, Lee SH, Hwang JH, Ryu JK, Kim YT.  Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.  PLoS ONE  2018    PubMed ID: 30557411
4339  Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M.  FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.  Cancer Sci.  2018    PubMed ID: 30302867
4347  Lin HY, Tey SL, Ho Y, Chin YT, Wang K, Whang-Peng J, Shih YJ, Chen YR, Yang YN, Chen YC, Liu YC, Tang HY, Yang YS.  Heteronemin Induces Anti-Proliferation in Cholangiocarcinoma Cells via Inhibiting TGF-β Pathway.  Mar Drugs  2018    PubMed ID: 30563284
4486  Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, Calderaro J, Barbour A, Raggi C, Wennerberg K, Wang XW, Lautem A, Roberts LR, Andersen JB.  Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.  Hepatology  2018  68(3):949-963  PubMed ID: 29278425
14301  Wang J, Zhang ZG, Ding ZY, Dong W, Liang HF, Chu L, Zhang BX, Chen XP.  IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC  J Surg Res  2018  231:116-125  PubMed ID: 30278918
14913  Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.  Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity  Dis Model Mech  2018  11(8):dmm03305  PubMed ID: 29666220
10290  Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.  High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.  Mol. Carcinog.  2017  56:2146-2157  PubMed ID: 28467612
10312  Račkauskas R, Zhou D, Ūselis S, Strupas K, Herr I, Schemmer P.  Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.  Oncol. Rep.  2017  37:3660-3666  PubMed ID: 28498473
10363  Li P, Zhang L, Yang M, Qi M, Jin X, Han B.  Cul4B is a novel prognostic marker in cholangiocarcinoma.  Oncol Lett  2017  14:1265-1274  PubMed ID: 28808481
10461  Nooron N, Ohba K, Takeda K, Shibahara S, Chiabchalard A.  Dysregulated Expression of MITF in Subsets of Hepatocellular Carcinoma and Cholangiocarcinoma.  Tohoku J. Exp. Med.  2017  242:291-302  PubMed ID: 28794318
5430  Li C, Imai M, Yamasaki M, Hasegawa S, Takahashi N.  Effects of Pre- and Post-Administration of Vitamin A on the Growth of Refractory Cancers in Xenograft Mice.  Biol Pharm Bull  2017  40(4):486-494  PubMed ID: 28100867
3727  Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM  K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.  Mol Oncol  2017  11(9):1130-1142  PubMed ID: 28544747
5767  Ito M, Sun S, Fukuhara T, Suzuki R, Tamai M, Yamauchi T, Nakashima K, Tagawa Y, Okazaki S, Matsuura Y, Wakita T, Suzuki T.  Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation.  Oncotarget  2017  8(33):53899-53915  PubMed ID: 28903311
3923  Yoshitsugu OHNUKI, Takumi KONDO, Hiroshi KUROSAWA  ROCK INHIBITOR Y-27632 USED DURING CELL AGGREGATE FORMATION ADVERSELY AFFECTS THE EARLY CARDIAC DIFFERENTIATION OF HUMAN iPS CELLS  Tiss Cult Res Commun  2017  36:21–29 
14252  Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.  Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification  Int J Oncol  2017  50(1):129-140.  PubMed ID: 27922671
14305  Hu MH, Chen LJ, Chen YL, Tsai MS, Shiau CW, Chao TI, Liu CY, Kao JH, Chen KF.  Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma  Oncotarget  2017  8(39):65077-65089  PubMed ID: 29029413
14527  Ling S, Xie H, Yang F, Shan Q, Dai H, Zhuo J, Wei X, Song P, Zhou L, Xu X, Zheng S.  Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1  J Hematol Oncol  2017  10(1):59  PubMed ID: 28241849
14568  Su Lin, Cheng He, Min-Fang Wang, Yin-Lian Wu, Jian Lin, Yi Liu, Yue-Yong Zhu  shRNA-mediated silencing of PKHD1 gene promotes proliferation, migration and invasion of human intrahepatic cholangiocarcinoma HuCCT-1 cells  Int J Clin Exp Pathol  2017  10(3):2496-2509 
14636  Trinh SX, Nguyen HT, Saimuang K, Prachayasittikul V, Chan On W.  Metformin Inhibits Migration and Invasion of Cholangiocarcinoma Cells  Asian Pac J Cancer Prev  2017  18(2):473-477  PubMed ID: 28345832
14652  Tsukagoshi M, Araki K, Yokobori T, Altan B, Suzuki H, Kubo N, Watanabe A, Ishii N, Hosouchi Y, Nishiyama M, Shirabe K, Kuwano H.  Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins  Oncotarget  2017  8(26):42159-42172  PubMed ID: 28178675
7120  Agarinis C, Orsini V, Megel P, Abraham Y, Yang H, Mickanin C, Myer V, Bouwmeester T, Tchorz JS, Parker CN.  Activation of Yap-Directed Transcription by Knockdown of Conserved Cellular Functions.  J Biomol Screen  2016  21:269-76  PubMed ID: 26637552
9516  Samatiwat P, Takeda K, Satarug S, Ohba K, Kukongviriyapan V, Shibahara S.  Induction of MITF expression in human cholangiocarcinoma cells and hepatocellular carcinoma cells by cyclopamine, an inhibitor of the Hedgehog signaling.  Biochem. Biophys. Res. Commun.  2016  470:144-9  PubMed ID: 26773496
9668  Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.  Src as a Therapeutic Target in Biliary Tract Cancer.  Mol. Cancer Ther.  2016  15:1515-24  PubMed ID: 27196758
9700  Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, Kalthoff H, Egberts JH, Braun F.  Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.  BMC Cancer  2016  16:322  PubMed ID: 27206490
3735  Saha SK et al  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123
6235  Li C, Imai M, Matsuura T, Hasegawa S, Yamasaki M, Takahashi N.  Inhibitory Effects of Retinol Are Greater than Retinoic Acid on the Growth and Adhesion of Human Refractory Cancer Cells.  Biol Pharm Bull  2016  39(4):636-40  PubMed ID: 26822412
14116  Huyen NT, Prachayasittikul V, Chan-On W.  Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation  J Hepatobiliary Pancreat Sci  2016  23(7):397-405  PubMed ID: 27107220
14138  Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.  Therapeutic implication of HER2 in advanced biliary tract cancer  Oncotarget  2016  7(36):58007-58021  PubMed ID: 27517322
7424  Xu YF, Ge FJ, Han B, Yang XQ, Su H, Zhao AC, Zhao MH, Yang YB, Yang J.  High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.  World J. Gastroenterol.  2015  21:3256-65  PubMed ID: 25805932
7429  Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A.  DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.  PLoS ONE  2015  10:e0120545  PubMed ID: 25799509
10114  Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Clément B, Garin E.  Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.  J Vasc Interv Radiol  2015  26:1874-78.e2  PubMed ID: 26596183
3736  Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T.  Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.  Mol Cancer Ther.  2015  14(9):1985-93  PubMed ID: 26141945
13740  Guo S, Liu HD, Liu YF, Liu L, Sun Q, Cui XJ.  Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma  Tumour Biol  2015  36(1):353-64  PubMed ID: 25262276
14311  Chan-On W, Huyen NT, Songtawee N, Suwanjang W, Prachayasittikul S, Prachayasittikul V.  Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells  Drug Des Devel Ther  2015  9:2033-47  PubMed ID: 25897210
15124  Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, Cornella H, Castillo-Martin M, Pinyol R, Kasai Y, Roayaie S, Thung SN, Fuster J, Schwartz ME, Waxman S, Cordon-Cardo C, Schadt E, Mazzaferro V, Llovet JM.  Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma  Nat Commun  2015  6:6087  PubMed ID: 25608663
15166  Yang H, Lu X, Liu Z, Chen L, Xu Y, Wang Y, Wei G, Chen Y.  FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells  Oncotarget  2015  6(8):6310-25  PubMed ID: 25749036
14930  Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A.  Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater  Int J Oncol  2014  44(4):1139-45  PubMed ID: 2448159
12544  Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T.  Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma  Hepatol Res  2013  43(9):959-69  PubMed ID: 23369163
12868  Yoshida M, Takimoto R, Murase K, Sato Y, Hirakawa M, Tamura F, Sato T, Iyama S, Osuga T, Miyanishi K, Takada K, Hayashi T, Kobune M, Kato J.  Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach  PLoS One  2012  7(7):e39545  PubMed ID: 22808043
7767  Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T.  Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.  Br. J. Cancer  2011  105:131-8  PubMed ID: 21673683
7898  Iwahashi S, Ishibashi H, Utsunomiya T, Morine Y, Ochir TL, Hanaoka J, Mori H, Ikemoto T, Imura S, Shimada M.  Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.  J. Med. Invest.  2011  58:106-9  PubMed ID: 21372494
7971  Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, Iwabuchi Y, Shibata H.  Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis.  Cancer Sci.  2011  102:1045-51  PubMed ID: 21272158
13665  Kamigaki M, Sasaki T, Serikawa M, Inoue M, Kobayashi K, Itsuki H, Minami T, Yukutake M, Okazaki A, Ishigaki T, Ishii Y, Kosaka K, Chayama K.  Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells  Int J Oncol  2011  39(3):561-8  PubMed ID: 21687941
13715  Kudo C, Yamakoshi H, Sato A, Nanjo H, Ohori H, Ishioka C, Iwabuchi Y, Shibata H.  Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo  BMC Pharmacol  2011  11:4  PubMed ID: 21619659
15724  Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H.  E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma  Br J Cancer  2011  105(12):1885-93  PubMed ID: 22068819
13667  Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T.  Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment  Cancer Sci  2010  101(4):882-8  PubMed ID: 20088962
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309
15602  Guleng B, Tateishi K, Ohta M, Asaoka Y, Jazag A, Lin LJ, Tanaka Y, Tada M, Seto M, Kanai F, Kawabe T, Omata M.  Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity  J Gastroenterol   2006  41(12):1238-9  PubMed ID: 17287906



Back Back Return Top Page